Skip to main content

Table 1 Baseline characteristics of the study population

From: Prognostic value of rising mean platelet volume during hospitalization in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention

Variable Survivors (n = 370) Non-survivors (n = 110) P-value
Age (year) 58 ± 11 68 ± 13 <  0.001
Female n (%) 80 (22) 37 (34) 0.010
Hypertension n (%) 151 (41) 63 (57) 0.002
Diabetes mellitus n (%) 78 (21) 37 (34) 0.007
Hyperlipidemia n (%) 76 (21) 24 (22) 0.772
Current smoking n (%) 168 (45) 40 (36) 0.098
Previous CAD n (%) 64 (17) 27 (25) 0.089
Prior stroke/TIA n (%) 5 (1) 9 (8) <  0.001
Killip class ≥2 n (%) 21 (6) 20 (18) <  0.001
Multi-vessel disease n (%) 132 (36) 57 (52) 0.002
GP IIb/IIIa inhibitors n (%) 107 (29) 37 (34) 0.343
Medication at discharge
 Beta-blocker n (%) 319 (86) 82 (73) 0.004
 Statin n (%) 312 (84) 85 (77) 0.086
 ACE-I/ARB n (%) 315 (85) 76 (69) <  0.001
 DAPT n (%) 365 (99) 107 (97) 0.322
Infarct related artery 0.097
 LAD n (%) 170 (46) 50 (46)  
 Cx n (%) 57 (15) 8 (7)  
 RCA n (%) 129 (35) 49 (45)  
 Others n (%) 14 (4) 3 (2)  
Outcomes
 30-day death n (%) 0 (0) 19 (17) <  0.001
 Stroke n (%) 7 (2) 5 (5) 0.118
 HF admission n (%) 7 (2) 15 (14) <  0.001
 Myocardial reinfarction n (%) 30 (8) 8 (7) 0.776
 TVR n (%) 45 (12) 11 (10) 0.535
  1. HF heart failure, CAD coronary artery disease, TIA transient ischemic attack, ACE-I angiotensin-converting enzyme inhibitors, ARB angiotensin receptor blocker, TVR; target vessel revascularization, DAPT dual antiplatelet therapy